ETF Building Blocks Content Hub There Could Be Signs of Life for Biotech ETFs By Todd ShriberFebruary 6, 2024
ETF Building Blocks Content Hub How ETF Investors Can Take Advantage of Deal Activity By Roxanna Islam, CFA, CAIAJanuary 18, 2024
Beyond Basic Beta Content Hub What’s Now Inside Some Fundamentally Focused ETFs By Todd RosenbluthJanuary 8, 2024
ETF Building Blocks Content Hub Biotech ETF SBIO’s Momentum Strong to End 2023 By Nick Peters-GoldenDecember 28, 2023
ETF Building Blocks Content Hub Biotech ETF SBIO Sees Buy Signal Amid Hot Returns By Nick Peters-GoldenDecember 14, 2023
Energy Infrastructure Content Hub VettaFi Voices On: The Outlook for 2024 By Heather BellDecember 8, 2023
ETF Building Blocks Content Hub Play US Gene Treatment Approval in SBIO By Nick Peters-GoldenDecember 7, 2023
ETF Building Blocks Content Hub Innovation Could Propel Biotechnology Bounce By Todd ShriberOctober 31, 2023
ETF Building Blocks Content Hub 3 Growth-Minded ETFs to Play Fed Rate Pause By Nick Peters-GoldenJune 13, 2023
ETF Building Blocks Content Hub ALPS’ Biotech ETF SBIO Week’s Top Performer By Nick Peters-GoldenApril 24, 2023
ETF Building Blocks Content Hub Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
ETF Building Blocks Content Hub Biotech M&A Could Finally Be Ready to Rebound By Tom LydonFebruary 23, 2023
ETF Building Blocks Content Hub Look to SBIO for Biotech Exposure By Elle Caruso FitzgeraldDecember 12, 2022
ETF Building Blocks Content Hub Gene Deal Adds New Dimension to Biotech ETF SBIO By Nick Peters-GoldenNovember 16, 2022
ETF Building Blocks Content Hub SBIO Rallied While Major Indexes Declined Last Week By Elle Caruso FitzgeraldOctober 4, 2022
ETF Building Blocks Content Hub SBIO Outpaced XBI, IBB in Volatile Last Week By Elle Caruso FitzgeraldSeptember 21, 2022
ETF Building Blocks Content Hub SBIO Was ALPS’ Top Performing ETF in August By Elle Caruso FitzgeraldSeptember 1, 2022
